Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia

PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituximab can clear MRD, but long-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Chihara, Dai, Arons, Evgeny, Stetler-Stevenson, Maryalice, Yuan, Constance M., Wang, Hao-Wei, Zhou, Hong, Raffeld, Mark, Xi, Liqiang, Steinberg, Seth M., Feurtado, Julie, James, Lacey, Wilson, Wyndham, Braylan, Raul C., Calvo, Katherine R., Maric, Irina, Dulau-Florea, Alina, Kreitman, Robert J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2020
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213585/
https://ncbi.nlm.nih.gov/pubmed/32109194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02250
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller